- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | OS Therapies: OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies | 264 | Newsfile | New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is... ► Artikel lesen | |
| Mo | OS Therapies: OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 303 | Newsfile | Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's request, Type D Meeting expected in March 2026 to review Comparative... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 15.01. | OS Therapies Bone Cancer Trial Data Strengthens FDA Case | 3 | Benzinga.com | ||
| 15.01. | OS Therapies: OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 140 | Newsfile | Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (Pre-specified pathway analysis strategy developed as... ► Artikel lesen | |
| 14.01. | OS Therapies: OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary | 374 | Newsfile | OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first... ► Artikel lesen | |
| 12.01. | OS Therapies: OS Therapies Enters into Warrant Inducement Agreements | 196 | Newsfile | $7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet proceeds to fund OST-HER2 regulatory approval... ► Artikel lesen | |
| 12.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | OS Therapies provides first half 2026 corporate outlook | 3 | Seeking Alpha | ||
| 05.01. | OS Therapies: OS Therapies Provides First Half 2026 Corporate Outlook | 407 | Newsfile | Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary... ► Artikel lesen | |
| 09.12.25 | OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 365 | Newsfile | Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study designBiomarker data advanced as key pre-specified surrogate clinical efficacy endpoint... ► Artikel lesen | |
| 05.12.25 | OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility | 485 | Newsfile | U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency... ► Artikel lesen | |
| 25.11.25 | OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization | 359 | Newsfile | New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today... ► Artikel lesen | |
| 20.11.25 | OS Therapies to spin off OS Animal Health into a standalone public company | 5 | Seeking Alpha | ||
| 20.11.25 | OS Therapies plans to spin off animal health unit as public company | 5 | Investing.com | ||
| 20.11.25 | OS Therapies to Spinoff OS Animal Health into Standalone Public Company | 365 | Newsfile | Successful preliminary discussion with NYSE representatives and potential investorsOS Therapies shareholders to receive direct equity participation in new listing'Shelter Me: Cancer Pioneers' film... ► Artikel lesen | |
| 17.11.25 | OS Therapies: Aktie fällt nach höherem Quartalsverlust im Zuge von Zulassungsvorbereitungen | 16 | Investing.com Deutsch | ||
| 17.11.25 | OS Therapies GAAP EPS of -$0.21 misses by $0.08 | 5 | Seeking Alpha | ||
| 17.11.25 | OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update | 360 | Newsfile | Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting regarding Phase 2b clinical trial of OST-HER2: prevention or delay of recurrent... ► Artikel lesen | |
| 31.10.25 | OS Therapies Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.10.25 | OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 382 | Newsfile | New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| IMMUNIC | 0,511 | -1,73 % | EQS-News: Immunic AG: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Conference/Study results
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,920 | +7,39 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,617 | +4,15 % | ANAVEX LIFE SCIENCES CORP kurz vor dem entscheidenden Ausbruch | ||
| ARCTURUS THERAPEUTICS | 7,560 | +7,69 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,200 | -1,37 % | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | ||
| PROTALIX BIOTHERAPEUTICS | 2,420 | -0,82 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU | Committee
for
Medicinal
Products
for
Human
Use
(CHMP)
issues
a
positive
opinion following re-examination, which
will
be reviewed by
the... ► Artikel lesen | |
| GEOVAX LABS | 2,700 | +4,65 % | EQS-News: GeoVax Labs, Inc.: GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement | GeoVax, Inc. / Key word(s): Financial
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
08.01.2026 / 15:03 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| SCILEX | 8,440 | +7,38 % | Scilex Holding Co - 8-K, Current Report | ||
| INVIVYD | 1,585 | -7,85 % | Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration | LIBERTY is part of the Company's broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits... ► Artikel lesen | |
| MEIRAGTX | 6,150 | -2,38 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,812 | +8,20 % | Tenaya Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| UNICYCIVE THERAPEUTICS | 6,690 | +8,08 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,385 Euro und damit +9,06 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.